- Home
- BIO vs BXP Comparison
BIO vs BXP Comparison
Compare BIO & BXP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BIO
- BXP
- Stock Information
- Founded
- BIO 1952
- BXP 1970
- Country
- BIO United States
- BXP United States
- Employees
- BIO N/A
- BXP N/A
- Industry
- BIO Biotechnology: Laboratory Analytical Instruments
- BXP Real Estate Investment Trusts
- Sector
- BIO Industrials
- BXP Real Estate
- Exchange
- BIO Nasdaq
- BXP Nasdaq
- Market Cap
- BIO 9.2B
- BXP N/A
- IPO Year
- BIO N/A
- BXP 1997
- Fundamental
- Price
- BIO $245.57
- BXP $67.80
- Analyst Decision
- BIO Strong Buy
- BXP Buy
- Analyst Count
- BIO 4
- BXP 13
- Target Price
- BIO $415.25
- BXP $80.85
- AVG Volume (30 Days)
- BIO 397.4K
- BXP 1.5M
- Earning Date
- BIO 05-06-2025
- BXP 04-29-2025
- Dividend Yield
- BIO N/A
- BXP 5.81%
- EPS Growth
- BIO N/A
- BXP N/A
- EPS
- BIO N/A
- BXP 0.09
- Revenue
- BIO $2,566,500,000.00
- BXP $3,380,319,000.00
- Revenue This Year
- BIO $1.11
- BXP $1.59
- Revenue Next Year
- BIO $4.55
- BXP $2.97
- P/E Ratio
- BIO N/A
- BXP $831.25
- Revenue Growth
- BIO N/A
- BXP 4.45
- 52 Week Low
- BIO $235.84
- BXP $56.46
- 52 Week High
- BIO $387.99
- BXP $90.11
- Technical
- Relative Strength Index (RSI)
- BIO 36.97
- BXP 47.41
- Support Level
- BIO $235.84
- BXP $67.82
- Resistance Level
- BIO $249.37
- BXP $69.43
- Average True Range (ATR)
- BIO 7.74
- BXP 1.68
- MACD
- BIO 1.47
- BXP 0.09
- Stochastic Oscillator
- BIO 39.59
- BXP 61.96
About BIO Bio-Rad Laboratories Inc.
Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and sells products and solutions for the clinical diagnostics and life sciences markets. In clinical diagnostics (56% of sales), Bio-Rad sells test systems and specialized quality controls for clinical laboratories. In life sciences (44% of sales), it develops and manufactures instruments and reagents used in research, biopharmaceutical production, and food testing and has a leadership position in dPCR technology. The company is geographically diverse, with major markets in the Americas (42% of 2023 sales), Europe (31%), Asia (31%), and other (6%). Bio-Rad owns approximately 33% of Sartorius, a lab and bioprocessing supplier that specializes in single-use technology used in biologics manufacturing.